Advanced ovarian cancer: the case for personalized treatment

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • Primary debulking surgery (PDS) was associated with improved outcomes, and neoadjuvant chemotherapy (NACT) may improve survival in those with residual disease after PDS.

Why this matters

 

 

  • Not all patients with stage III or IV ovarian cancers benefit from 1 standard approach, PDS or NACT, and criteria to optimize patient selection are needed.

Study design

 

 

  • Retrospective study that included 263 patients treated for stage III-IV ovarian cancers between 2003 and 2015 at an academic medical center.
  • Funding: Montreal-Israel Cancer Research Foundation; Gloria Shapiro Fund; Weekend to End Women Cancers; Levy Family Fund; Astra Zeneca Inc.

Key results

 

 

  • Improved PFS and OS were observed after PDS vs NACT.
  • PDS patients with no residual disease after surgery had significantly better OS and PFS vs all other groups (P-values=.001); the opposite was observed for NACT patients with residual disease after interval debulking surgery.
  • NACT patients with complete cytoreduction had better OS and PFS vs PDS patients who did not achieve complete cytoreduction.
  • Results do not support an association of NACT with increased risk of developing platinum resistance.

Limitations

 

 

  • Retrospective and single-center design.